Global Networking Against Malaria

Announcements Calendar RBM MIM Networks and Databases More on the Web News About MFI DAM Home

Bibliography

Research Toward a Malaria Vaccine

This is a bibliography of references concerning research toward a malaria vaccine. References are added as time permits. This bibliography is not comprehensive at this time. Owing to size, this bibliography is split into two pages. An older bibliography is at National Library of Medicine.





  1. Ahlborg, N., I.T. Ling, A.A. Holder, and E.M. Riley. 2000. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). Infect. Immun. 68(4):2102-2109. Abstract.
  2. Ariey, F., W. Chalvet, D. Hommel, C. Peneau, A. Hulin, O. Mercereau-Puijalon, J.B. Duchemin, J.L. Sarthou, J.M. Reynes, and T. Fandeur. 1999. Plasmodium falciparum parasites in French Guiana: limited genetic diversity and high selfing rate. Amer. J. Trop. Med. Hyg. 61(6):978-985. Abstract.
  3. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, et al. 1987. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1(8545):1277-1281. Abstract.
  4. Benjamin, P.A., I.T. Ling, G. Clottey, L.M. Valero, S.A. Ogun, S.L. Fleck, D. Walliker, W.D. Morgan, B. Birdsall, J. Feeney, and A.A. Holder. 1999. Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies. Mol. Biochem. Parasitol. 104(2):147-156. Abstract.
  5. Bhattacharya, P.R., M. Kumar, and R.H. Das. 1999. Surprisingly little polymorphism in the merozoite-surface-protein-2 (MSP-2) gene of Indian Plasmodium falciparum. Ann. Trop. Med. Parasitol. 93(6):561-564. Abstract.
  6. Brown AE, Singharaj P, Webster HK, Pipithkul J, Gordon DM, Boslego JW, Krinchai K, Su-archawaratana P, Wongsrichanalai C, Ballou WR, et al. 1994. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine. 12(2):102-108. Abstract.
  7. Brown, G.V. 1999. Progress in the development of malaria vaccines: context and constraints. Parassitologia. 41(1-3):429-432. Abstract.
  8. Carvalho, L.H., C. J. Fontes, and A.V. Krettli. 1999. Cellular responses to Plasmodium falciparum major surface antigens and their relationship to human activities associated with malaria transmission. Amer. J. Trop. Med. Hyg. 60(4):674-679. Abstract.
  9. Chitarra, V., I. Holm, G.A. Bentley, S. Petres, and S. Longacre. 1999. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate.Mol. Cell. 3(4):457-464. Abstract.
  10. Collins, W.E., D.C. Kaslow, J.S. Sullivan, C.L. Morris, G.G. Galland, C. Yang, A.M. Saekhou, L. Xiao, and A.A. Lal. 1999. Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys. Amer. J. Trop. Med. Hyg. 60(3):350-356. Abstract.
  11. Conway, D.J., C. Roper, A.M. Oduola, D.E. Arnot, P.G. Kremsner, M.P. Grobusch, C.F. Curtis, and B.M. Greenwood. 1999. High recombination rate in natural populations of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 96(8):4506-4511. Abstract.
  12. Da Silveira, L.A., M.L. Dorta, E.A. Kimura, A.M. Katzin, F. Kawamoto, K. Tanabe, and M.U. Ferreira. 1999. Allelic diversity and antibody recognition of Plasmodium falciparum merozoite surface protein 1 during hypoendemic malaria transmission in the Brazilian amazon region. Infect Immun. 67(11):5906-5916. Abstract.
  13. Davis, J.R. 1994. Laboratory methods for the conduct of experimental malaria challenge of volunteers. Vaccine. 12(4):321-327. Abstract.
  14. Diallo, T.O., C.M. Nguer, A. Dieye, A. Spiegel, R. Perraut, and O. Garraud. 1999. Immune responses to P. falciparum-MSP1 antigen: lack of correlation between antibody responses and the capacity of peripheral cellular immune effectors to respond to this antigen in vitro. Immunol. Lett. 67(3):217-221. Abstract.
  15. Diallo, T.O., C.M. Nguer, A. Tall, A. Diouf, A. Spiegel, R. Perraut, and O. Garraud. 1999. [Antibodies specific to Plasmodium falciparum antigens in immune individuals: III. Seasonalcourse of the response to a major antigen of the asexual blood forms in two sites of different malaria exposure]. [in French]. Dakar Med. 44(1):63-68. Abstract
  16. Dodoo, D., T.G. Theander, J.A. Kurtzhals, K. Koram, E. Riley, B.D. Akanmori, F.K. Nkrumah, and L. Hviid. 1999. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect. Immun. 67(5):2131-2137. Abstract.
  17. Doherty, J.F., M. Pinder, N. Tornieporth, C. Carton, L. Vigneron, P. Milligan, W.R. Ballou, C.A. Holland, K.E. Kester, G. Voss, P. Momin, B.M. Greenwood, K.P. McAdam, and J. Cohen J. 1999. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Amer. J. Trop. Med. Hyg. 61(6):865-868. Abstract.
  18. Dolo, A., D. Modiano, O. Doumbo, A. Bosman, T. Sidibe, M.M. Keita, S. Naitza, K.J. Robson, and A. Crisanti. 1999. Thrombospondin related adhesive protein (TRAP), a potential malaria vaccine candidate.Parassitologia. 41(1-3):425-428. Abstract.
  19. Egan, A.F., M.J. Blackman, and D.C. Kaslow. 2000. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect. Immun. 68(3):1418-1427. Abstract.
  20. Egan, A.F., P. Burghaus, P. Druilhe, A.A. Holder, and E.M. Riley. 1999. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21(3):133-139. Abstract. Abstract from publisher.
  21. Farnert, A., I. Rooth, Svensson, G. Snounou, and A. Bjorkman. 1999. Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J. Infect. Dis. 179(4):989-995. Abstract.
  22. Fernandez, V., M. Hommel, Q. Chen, P. Hagblom, and M. Wahlgren. 1999. Small, clonally variant antigens expressed on the surface of the Plasmodium falciparum-infected erythrocyte are encoded by the rif gene family and are the target of human immune responses. J. Exp. Med. 190(10):1393-1404. Abstract.
  23. Ferreira, M.U., O. Kaneko, M. Kimura, Q. Liu, F. Kawamoto, and K. Tanabe. 1998. Allelic diversity at the merozoite surface protein-1 (MSP-1) locus in natural Plasmodium falciparum populations: a brief overview. Mem. Inst. Oswaldo Cruz. 93(5):631-638. Abstract. Published erratum appears in Mem. Inst. Oswaldo Cruz - 1999 - 94(1):138.
  24. Ferreira, M.U., Q. Liu, M. Kimura, B.T. Ndawi. K. Tanabe, and F. Kawamoto. 1998. Allelic diversity in the merozoite surface protein-1 and epidemiology of multiple-clone Plasmodium falciparum infections in northern Tanzania. J. Parasitol. 84(6):1286-1289. Abstract.
  25. Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V. 2000. Antibodies against thrombospondin-related anonymous protein Do not inhibit plasmodium sporozoite infectivity In vivo. Infect. Immun. 68(6):3667-3673. Abstract.
  26. Garraud, O., A. Diouf, I. Holm, C.M. Nguer, A. Spiegel, R. Perraut, and S. Longacre. 1999. Secretion of parasite-specific immunoglobulin G by purified blood B lymphocytes from immune individuals after in vitro stimulation with recombinant Plasmodium falciparum merozoite surface protein-119 antigen. Immunology. 97(2):204-210. Abstract. Abstract from publisher.
  27. Garraud, O., A. Diouf, C.M. Nguer, A. Dieye, S. Longacre, D.C. Kaslow, A.A. Holder, A. Tall, J.F. Molez, R. Perraut, and O. Mercereau-Puijalon. 1999. Different Plasmodium falciparum recombinant MSP1(19) antigens differ in their capacities to stimulate in vitro peripheral blood T lymphocytes in individuals from various endemic areas. Scand. J. Immunol. 49(4):431-440. Abstract. Abstract from publisher.
  28. Genton, B., F. Al-Yaman, R. Anders, A. Saul, G. Brown, D. Pye, D.O. Irving, W.R. Briggs, A. Mai, M. Ginny, T. Adiguma, L. Rare, A. Giddy, R. Reber-Liske, D. Stuerchler, and M.P. Alpers. 2000. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine. 18(23):2504-2511. Abstract.
  29. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, et al. 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171(6):1576-1585. Abstract.
  30. Gozalo, A., C. Lucas, M. Cachay, B.T. Wellde, T. Hall, B. Bell, J. Wood, D. Watts, M. Wooster, J.A. Lyon, J.K. Moch, J.D. Haynes, J.S. Williams, C. Holland, E. Watson, K.E. Kester, D.C. Kaslow, and W.R. Ballou. 1998. Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19). Amer. J. Trop. Med. Hyg. 59(6):991-997. Abstract.
  31. Haddad, D., G. Snounou, D. Mattei, I.G. Enamorado, J. Figueroa, S. Stahl, and K. Berzins. 1999. Limited genetic diversity of Plasmodium falciparum in field isolates from Honduras. Amer. J. Trop. Med. Hyg. 60(1):30-34. Abstract.
  32. Holder, A.A., J.A. Guevara Patino, C. Uthaipibull, S.E. Syed, I.T. Ling, T. Scott-Finnigan, and M.J. Blackman. 1999. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia. 41(1-3):409-414. Abstract. Review.
  33. Hui, G.S., and C.N. Hashimoto. 1998. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. Infect. Immun. 66(11):5329-5336. Abstract.
  34. Jiang, G., C. Daubenberger, W. Huber, H. Matile, M. Tanner, and G. Pluschke. 2000. Sequence diversity of the merozoite surface protein 1 of Plasmodium falciparum in clinical isolates from the Kilombero District, Tanzania. Acta Trop. 74(1):51-61. Abstract.
  35. Johnson, A., R. Leke, L. Harun, C. Ginsberg, J. Ngogang, A. Stowers, A. Saul, and I.A. Quakyi. 2000. Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2. Infect. Immun. 68(4):2231-2236. Abstract.
  36. Keitel, W.A., K.E. Kester, R.L. Atmar, A.C. White, N.H. Bond, C.A. Holland, U. Krzych, D.R. Palmer, A. Egan, C. Diggs, W.R. Ballou, B.F. Hall, and D. Kaslow. 1999. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 18(5-6):531-539. Abstract.
  37. Kitua, A.Y., H. Urassa, M. Wechsler, T. Smith, P. Vounatsou, N.A. Weiss, P.L. Alonso, and M. Tanner. 1999. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol. 21(6):307-317. Abstract. Abstract from publisher.
  38. Konate, L., J. Zwetyenga, C. Rogier, E. Bischoff, D. Fontenille, A. Tall, A. Spiegel, J.F. Trape, and O. Mercereau-Puijalon. 1999. Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans. R. Soc. Trop. Med. Hyg. 93 Suppl. 1:21-28. Abstract.
  39. Kumar, S., W. Collins, A. Egan, A. Yadava, O. Garraud, M.J. Blackman, J.A. Guevara Patino, C. Diggs, and D.C. Kaslow. 2000. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun. 68(4):2215-2223. Abstract.
  40. Kwiatkowski, D., and K. Marsh. 1997. Development of a malaria vaccine. Lancet. 350(9092):1696-1701. Abstract.
  41. Lalitha, P.V., P. Malhotra, R. Chattopadhyay, and V.S. Chauhan. 1999. Plasmodium falciparum: variations in the C-terminal cysteine-rich region of the merozoite surface protein-1 in field samples among Indian isolates. Exp. Parasitol. 92(1):12-18. Abstract. Abstract from publisher.
  42. Lawrence, G., Q.Q. Cheng, C. Reed, D. Taylor, A. Stowers, N. Cloonan, C. Rzepczyk, A. Smillie, K. Anderson, D. Pombo, A. Allworth, D. Eisen, R. Anders, and A. Saul. 2000. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates ofPlasmodium falciparum in non-immune volunteers. Vaccine. 18(18):1925-1931. Abstract.
  43. Le, T.P., K.M. Coonan, R.C. Hedstrom, Y. Charoenvit, M. Sedegah, J.E. Epstein, S. Kumar, R. Wang, D.L. Doolan, J.D. Maguire, S.E. Parker, P. Hobart, J. Norman, and S.L. Hoffman. 2000. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.Vaccine. 18(18):1893-1901. Abstract.
  44. Matsumoto, S., H. Yukitake, H. Kanbara, and T. Yamada. 1999. Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1. Vaccine. 18(9-10):832-834. Abstract.





Back to MFI literature page

Last Revised 12 September 2000


Thank you for visiting the MFI Site!


Copyright © 1999-2000
Malaria Foundation International
All Rights Reserved.